Neumora Therapeutics (NMRA) Current Assets (2022 - 2026)

Neumora Therapeutics' Current Assets history runs 5 years deep, the most recent figure standing at $153.4 million for Q1 2026.

• In Q1 2026, Current Assets fell 39.8% year-over-year to $153.4 million; the TTM figure through Mar 2026 stood at $153.4 million (down 39.8% YoY), while the FY2025 annual figure was $190.5 million, down 39.33% from the prior year.
• Current Assets for Q1 2026 stood at $153.4 million, down from $190.5 million in the prior quarter.
• The five-year high for Current Assets was $525.7 million in Q3 2023, with the low at $153.4 million in Q1 2026.
• The 5-year median for Current Assets is $331.3 million (2024), against an average of $324.5 million.
• The sharpest annual moves came in 2023 and 2025: Current Assets grew 23.28% in 2023, then sank 49.2% in 2025.
• Neumora Therapeutics' Current Assets stood at $388.0 million in 2022, then gained by 23.28% to $478.3 million in 2023, then slumped by 34.34% to $314.1 million in 2024, then slumped by 39.33% to $190.5 million in 2025, then dropped by 19.47% to $153.4 million in 2026.
• Business Quant data shows NMRA's Current Assets at $153.4 million in Q1 2026, $190.5 million in Q4 2025, and $177.1 million in Q3 2025.